Nine Drug Formularies In Canada List Evenity® For Reimbursement For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk Of Fracture

April 3, 2024

Amgen Canada has announced EVENITY’s (romosozumab) inclusion in public formularies, marking a significant step in osteoporosis care for postmenopausal women.

EVENITY has been listed for reimbursement on nine of Canada’s public formularies. With this announcement most postmenopausal women in Canada will be able to access this biologic treatment which received Health Canada approval in 2019.

Click here to visit AMGEN Canada and read the full release .

To learn more about osteoporosis treatments visit https://osteoporosis.ca/treatments/

OC MAKES THE NEWS – RECENT ITEMS

Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario

February 20, 2025

Latest News Recently launched Apo-Teriparatide Injection now as a listed benefit in Ontario February 20, 2025 Apo-Teriparatide Injection ™ is a generic alternative to Forteo®. Osteoporosis pharmacologic therapies are classified […]

VIEW

2024 Gideon A. Rodan Excellence in Mentorship Award

August 16, 2024

Latest News 2024 Gideon A. Rodan Excellence in Mentorship Award Angela Cheung, M.D., Ph.D. is the recipient of the 2024 Gideon A. Rodan Excellence in Mentorship Award which is given […]

VIEW

Sandoz receives Health Canada approval for Jubbonti^®, first and only denosumab biosimilar for treatment of osteoporosis.

May 31, 2024

Latest News Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis. May 31, 2024 Health Canada has provided authorization to market Jubbonti® (denosumab […]

VIEW